China Resources Pharmaceutical Group Ltd. (DE:640)
FRANKFURT:640
640 Stock Chart & Stats
€0.49
€0.00(0.00%)
At close: 4:00 PM EST
€0.49
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.47 - €0.71
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€3.31B
Enterprise Value€103.60B
Total Cash (Recent Filing)€58.73B
Total Debt (Recent Filing)€104.87B
Price to Earnings (P/E)6.7
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.74Price Target Upside50.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Business ModelA vertically integrated model spanning distribution, retail and manufacturing provides diversified revenue streams and supply‑chain control. Over months this lowers margin volatility, enables cross-selling, and leverages logistics scale to sustain stable demand and operational resilience.
Consistent Revenue GrowthSteady, mid-single-digit revenue growth indicates durable market demand and effective commercial execution. Combined with modest gross margin improvement, this trend supports predictable top-line expansion, helps fund reinvestment in stores and products, and underpins cash flow stability.
Strong Cash GenerationRobust operating and free cash flow relative to reported earnings enhances earnings quality and financial flexibility. This persistent cash generation supports capex, working capital needs and dividend capability, providing a buffer versus cyclical stress and enabling measured strategic investment.
Bears Say
Rising LeverageMaterial debt growth and a higher debt-to-equity ratio materially raise financial risk over the medium term. Increased leverage amplifies interest expense sensitivity, limits flexibility for acquisitions or buybacks, and heightens vulnerability to tighter credit conditions or slower cash conversion.
Very Thin Net MarginsPersistently low net margins constrain the company's ability to translate revenue growth into bottom-line gains. This reduces internal funding capacity, leaves little room to absorb input cost inflation, and makes returns sensitive to small adverse changes in pricing or operating costs.
Cash Flow Vs Debt MismatchWhile cash generation is solid versus earnings, operating cash flow is small relative to the debt stock, limiting rapid deleveraging. This structural mismatch constrains balance-sheet repair options and increases refinancing and interest-rate exposure over the coming months.
China Resources Pharmaceutical Group Ltd. News
640 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was €0.47 and its highest was €0.71 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is €3.31B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. does not currently pay dividends.
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in DE:640
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€0.74 (50.54% Upside)
€0.74 (50.54% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
-17.45%
12-Months-Change
Fundamentals
Return on Equity
7.98%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
640 Stock 12 Month Forecast
Average Price Target
€0.74
▲(50.54% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---